Table 1. Comparison of randomized controlled trials involving switch maintenance therapy.
| Trial | Comparison | Patients (n) |
PFS (months) |
p-value/HR (95% CI) |
OS (months) |
p-value/HR (95% CI) |
Patients receiving maintenance drug (%) | Ref. |
|---|---|---|---|---|---|---|---|---|
| Fidias et al. | Immediate docetaxel | 153 | 5.7† | 0.001 | 12.3 | 0.085 | 95 | [8,22] |
| Placebo then delayed docetaxel | 156 | 2.7 | 9.7 | HR: 0.80 | 63 | |||
| JMEN | Pemetrexed | 441 | 4.3† | <0.0001 | 13.4† | 0.012 | 98 + 1‡ | [10] |
| Placebo | 222 | 2.6 | HR: 0.50 (0.42–0.61) |
10.6 | HR: 0.79 (0.65–0.95) |
18 | ||
| SATURN | Erlotinib | 437 | 2.8† | <0.001 | 12.0† | 0.009 | NR + 11‡ | [19] |
| Placebo | 447 | 2.6 | HR: 0.71 (0.62–0.82) |
11.0 | HR: 0.81 (0.70–0.95) |
21 | ||
| IFCT-GFPC 0502 | Gemcitabine | 149 | 3.8† | <0.0001 HR: 0.55 (0.43–0.70) |
12.1 | HR: 0.86 (0.66–1.12) |
60 (pemetrexed) | [20] |
| Erlotinib | 155 | 2.9† | 0.002 HR: 0.82 (0.73–0.93) |
11.8 | HR: 0.91 (0.80–1.04) |
63 | ||
| Placebo | 152 | 1.9 | 10.7 | 76 |
†
Statistically superior result.
‡
Treatment on trial plus post-study treatment.
HR: Hazard ratio; IFCT-GFPC: Intergroupe Francophone de Cancérologie Thoracique – Groupe Français de Pneumo-Cancérologie; NR: Not reported; OS: Overall survival; PFS: Progression-free survival; SATURN: Sequential Tarceva in Unresectable NSCLC.